Domestic and Overseas Economic and Market Volatility Caused by COVID-19 and Other Factors
First written in FY2020-Q3. 7 of 13 entries say "Materialised", first in FY2020. Latest entry: FY2024.
Pharmarise Holdings moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2020: 112 of 175 companies on the "Worse" side.
56 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「COVID-19 was reclassified as a Category V infectious disease, and social activity normalized」
The impact of COVID-19 eased against the backdrop of its reclassification as a Category V infectious disease and the normalization of social activity, and was cited as a factor behind the recovery in merchandise business revenue. - FY2024-Q2MitigatedAnnual report
「Revenue growth in the convenience store and drugstore divisions, against the backdrop of an economic recovery as the impact of COVID-19 eased」
The easing of the impact of COVID-19 and the recovery in economic activity were cited as factors behind revenue growth in the merchandise business. - FY2023MaterialisedAnnual report
「A decline in revenue in the drugstore division of the merchandise business due to weaker COVID-19-related demand for sanitary products such as masks and the reaction to stay-at-home demand」
The decline in COVID-19-related demand and the reaction to stay-at-home demand continued to be reflected as factors behind lower revenue and increased losses in the merchandise business. - FY2023-Q1SoftenedAnnual report
「During the first quarter of the current consolidated cumulative period (1 June 2022 to 31 August 2022), Japan's economy was expected to recover as economic and social activity normalized while thorough measures were taken against COVID-19」
The disclosure changed to state that economic and social activity would normalize and the economy would recover under infection-control measures, indicating that the outlook for the impact of COVID-19 had weakened somewhat. However, downside risks were disclosed separately. - FY2022MaterialisedAnnual report
「As COVID-19 remained prolonged without subsiding, the dispensing pharmacy business continued to face a decline in the number of prescriptions resulting from restrictions on visits to medical institutions and patients' avoidance of medical visits, which led to longer prescription periods. In the merchandise business, the number of users at stores in central urban areas and elsewhere continued to decline due to the spread of working from home and the curtailment of corporate activities, affecting the performance of the Group.」
The decline in the number of prescriptions and users of stores in central urban areas due to the prolonged impact of COVID-19 continued to be reflected as factors affecting performance for the period. - FY2022-Q2RestatedAnnual report
「Going forward, economic conditions are expected to recover as measures are taken to prevent the spread of infection, but it remains necessary to pay close attention to the increasing downside risk from the spread of infection in Japan and overseas.」
While expressing expectations for an economic recovery, the company continues to cite downside risks from the spread of COVID-19 in Japan and overseas. - FY2022-Q1RestatedAnnual report
「Going forward, economic conditions are expected to recover as measures are taken to prevent the spread of infection, but it remains necessary to pay close attention to the increasing downside risk from the spread of infection in Japan and overseas.」
While expressing expectations for an economic recovery, the company continues to cite downside risks from the spread of COVID-19 in Japan and overseas. - FY2021MaterialisedAnnual report
「If COVID-19 does not subside and becomes prolonged, the dispensing pharmacy business will continue to face conditions such as a decline in the number of prescriptions, as restrictions on visits to medical institutions and patients' avoidance of medical visits result in longer prescription periods」
The impact of COVID-19 continued to be reflected in a decline in the number of prescriptions and users of the merchandise business during the period, and the risk of prolonged effects continues to be disclosed. - FY2021-Q3MaterialisedAnnual report
「Revenue increased due to contributions from Medical Front Co., Ltd., which became a consolidated subsidiary on 1 October 2019, Healthy Work Co., Ltd., which became a consolidated subsidiary on 1 March 2020, WEEK Co., Ltd., acquired on 31 March 2020, and Sun Medical Co., Ltd., acquired on 1 April 2020. However, revenue declined 0.3% year on year due to the impact of the April 2020 drug price revision, a decrease in the number of prescriptions resulting from COVID-19, and the impact of closing unprofitable stores.」
The impact of COVID-19 continued to be reflected in a decrease in the number of prescriptions and a 0.3% year-on-year decline in revenue. - FY2021-Q2MaterialisedAnnual report
「Revenue declined 0.4% year on year due to the April 2020 drug price revision, a decrease in the number of prescriptions resulting from the impact of COVID-19, and the impact of closing unprofitable stores.」
The impact of COVID-19 continued to be reflected in a decrease in the number of prescriptions and a 0.4% year-on-year decline in revenue. - FY2021-Q1MaterialisedAnnual report
「Profit was also significantly affected by COVID-19, and operating income (loss), ordinary income (loss), and quarterly net income (loss) attributable to owners of the parent all declined year on year.」
The impact of COVID-19 continued to be reflected in the year-on-year deterioration in operating income (loss), ordinary income (loss), and quarterly net income (loss) attributable to owners of the parent. - FY2020MaterialisedAnnual report
「Revenue declined year on year due to the impact of COVID-19, in addition to the impact of closing unprofitable stores.」
The impact of COVID-19 was explicitly identified as a factor behind the year-on-year decline in revenue. The risk of prolonged restrictions on visits to pharmacies and a decline in users of merchandise stores also remains. - FY2020-Q3First statedAnnual report
「In addition, although it is necessary to pay close attention to the impact of COVID-19 on the domestic and overseas economies, as well as developments in overseas economies, including developments surrounding trade issues, and fluctuations in financial and capital markets」
For the first time, explicitly identified the impact of COVID-19 on the domestic and overseas economies, overseas economic conditions, and fluctuations in financial and capital markets as new matters requiring attention in the economic environment.